phrykt

Pelthos Therapeutics Inc. (PTHS): who owns it and who trades it

As of Nov 16, 2026, PTHS insiders reported 24 open-market sales worth $486K and 2 purchases worth $1000K in the last 12 months, with 34% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ezra M Friedberg (Director), with $326K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pelthos Therapeutics

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PTHS

23 funds and institutions reported PTHS shares worth $38.5M at the end of Q2 2026, about 41% of the company. The largest holder is AIGH Capital Management LLC with 9.8%.

Funds and institutions (13F) 41%Everyone else 59%

10 largest owners, by share of the company

AIGH Capital Management LLC9.8%
Murchinson Ltd.9.1%
Ikarian Capital, LLC7.6%
Boothbay Fund Management, LLC3.0%
Vanguard Capital Management LLC2.9%
Cantor Fitzgerald, L. P.2.3%
J. Goldman & Co LP1.1%
Diadema Partners LP0.7%
Wexford Capital LP0.7%
Knott David M Jr0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
AIGH Capital Management LLC329,0989.81%$9.3MNew
Murchinson Ltd.304,3029.07%$8.6M+3%
Ikarian Capital, LLC256,5987.65%$7.3MNo change
Boothbay Fund Management, LLC101,9763.04%$2.9M+25%
Vanguard Capital Management LLC97,1342.89%$2.7M+4%
Cantor Fitzgerald, L. P.76,2462.27%$2.2M+84%
J. Goldman & Co LP38,0751.13%$1.1M-24%
Diadema Partners LP24,7730.74%$700KNo change
Wexford Capital LP22,3640.67%$632KNew
Knott David M Jr22,0730.66%$624K+5%
Citadel Advisors LLC15,0460.45%$425KNew
Geode Capital Management, LLC14,6500.44%$414K-4%
Pale Fire Capital SE12,9190.39%$365KNo change
1492 Capital Management LLC10,3800.31%$293KNew
Vanguard Fiduciary Trust Co9,8730.29%$279K+1%
State Street Corp9,8000.29%$277KNew
Persistent Asset Partners Ltd6,0070.18%$170KNo change
BlackRock, Inc.5,3240.16%$150KNew
UBS Group AG2,2170.07%$62.7K+190%
China Universal Asset Management Co., Ltd.2,1600.06%$61KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PTHS insiders reported $1000K of open-market purchases and $486K of sales. 34% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1000K
2 trades, 1 people
Sales, 12 months
$486K
24 trades, 5 people
Sales under a 10b5-1 plan
34%
Share of sale value
Latest trade
Oct 2, 2026
Filed Oct 6, 2026

Purchases and sales by month

$1000K$1000KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 2, 2026Ezra M FriedbergDirectorSale plan558$20.72$11.6KForm 4
Oct 2, 2026Peter GreenleafDirectorSale plan797$21.17$16.9KForm 4
Oct 2, 2026Matthew PaulsDirectorSale plan786$21.00$16.5KForm 4
Jul 2, 2026Ezra M FriedbergDirectorSale plan534$26.03$13.9KForm 4
Jul 2, 2026Ezra M FriedbergDirectorSale plan24$27.33$656Form 4
Jul 2, 2026Matthew PaulsDirectorSale plan94$27.36$2.6KForm 4
Jul 2, 2026Matthew PaulsDirectorSale plan692$26.00$18KForm 4
Jul 2, 2026Peter GreenleafDirectorSale plan712$26.00$18.5KForm 4
Jul 2, 2026Peter GreenleafDirectorSale plan85$27.27$2.3KForm 4
Jun 15, 2026Ezra M FriedbergDirectorSale plan224$27.12$6.1KForm 4
Jun 15, 2026Ezra M FriedbergDirectorSale plan59$27.94$1.6KForm 4
Jun 11, 2026Todd C DavisDirectorPurchase503$28.73$14.5KForm 4
Jun 11, 2026Todd C DavisDirectorPurchase35,445$27.80$985KForm 4
May 22, 2026Knuettel Francis IICFOSale1,500$26.84$40.3KForm 4
Apr 2, 2026Richard MalamutDirectorSale plan310$20.51$6.4KForm 4
Apr 2, 2026Richard MalamutDirectorSale plan280$21.36$6KForm 4
Apr 2, 2026Ezra M FriedbergDirectorSale plan293$20.51$6KForm 4
Apr 2, 2026Ezra M FriedbergDirectorSale plan265$21.36$5.7KForm 4
Apr 2, 2026Matthew PaulsDirectorSale plan371$21.36$7.9KForm 4
Apr 2, 2026Matthew PaulsDirectorSale plan415$20.52$8.5KForm 4
Apr 2, 2026Peter GreenleafDirectorSale plan420$20.52$8.6KForm 4
Apr 2, 2026Peter GreenleafDirectorSale plan377$21.36$8.1KForm 4
Nov 25, 2025Ezra M FriedbergDirectorSale5,999$28.00$168KForm 4
Nov 25, 2025Ezra M FriedbergDirectorSale2,000$28.01$56KForm 4
Nov 25, 2025Ezra M FriedbergDirectorSale1$28.50$28Form 4
Nov 25, 2025Ezra M FriedbergDirectorSale2,000$28.14$56.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Todd C DavisDirector$1000K–Jun 11, 2026
Ezra M FriedbergDirector–$326KOct 2, 2026
Peter GreenleafDirector–$54.4KOct 2, 2026
Matthew PaulsDirector–$53.5KOct 2, 2026
Knuettel Francis IICFO, Treas & Secty–$40.3KMay 22, 2026
Richard MalamutDirector–$12.3KApr 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PTHS short interest

Low short interest. 4.1% of PTHS shares are sold short: about 1 share in 24. Over the last 12 reports the number of shares short went up 411%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 158,465 PTHS shares were sold short, 4.1% of the shares outstanding, up 11.4% from the report before. At the average daily volume of 79,298 shares, buying them all back would take about 2.0 trading days (days to cover).

Shares short, % of all shares

4.14%May 15Oct 304.67%

Days to cover

2.0May 15Oct 304.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026158,4654.14%+11%79,2982.0
Oct 15, 2026142,2503.72%+36%47,5163.0
Sep 30, 2026104,5732.73%+12%25,6864.1
Sep 15, 202693,7412.45%-10%43,4892.2
Aug 31, 2026104,3242.72%+8%50,5772.1
Aug 14, 202696,5282.52%+39%83,4991.2
Jul 31, 202669,5312.07%-2%109,5741.0
Jul 15, 202670,6702.11%+154%30,4452.3
Jun 30, 202627,7900.83%+32%28,1241.0
Jun 15, 202621,0510.63%-45%16,2611.3
May 29, 202638,1141.14%+23%23,6271.6
May 15, 202631,0170.92%-17%24,4051.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pelthos Therapeutics company events

Pelthos Therapeutics filed 15 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, restatement, auditor). The latest was on Oct 30, 2026.

  1. Oct 30, 2026LeadershipPelthos and Scott Plesha, its Chief Executive Officer, entered into a Second Amendment to his Executive Employment Agreement dated as of July 1, 2025, as amended. Filing
  2. Oct 1, 2026LeadershipAs described in Item 5.07 below, on September 29, 2026, at the 2026 Annual Meeting of Stockholders of Pelthos Therapeutics Inc., the Company’s stockholders approved the Pelthos Therapeutics Inc. 2026 Equity Incentive Plan, which replaces the Pelthos Therapeutics Inc. 2023 Equity Incentive Plan, as… Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Aug 13, 2026Restatement. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. Filing
  5. May 28, 2026AnnouncementShared information with investors. Filing
  6. May 21, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  7. May 14, 2026ResultsReleased financial results. Filing
  8. Apr 14, 2026AnnouncementShared information with investors. Filing
  9. Apr 10, 2026LeadershipThe Board of Directors of Pelthos Therapeutics Inc. appointed John M. Gay, age 49, to serve as Chief Financial Officer of the Company, effective April 10, 2026. Filing
  10. Mar 19, 2026ResultsReleased financial results. Filing
  11. Jan 13, 2026AgreementPelthos Therapeutics Inc., a Nevada corporation, LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company, as co-borrowers (together with the Company, the “ Borrowers ”)… Filing
  12. Jan 12, 2026LeadershipThe board of directors of Pelthos Therapeutics Inc., upon recommendation from the compensation committee of the Board following its annual assessment of the Board’s compensation program, approved the following changes to the cash and equity compensation of non-employee directors (as amended, the… Filing
  13. Jan 2, 2026AgreementPelthos Therapeutics Inc., a Nevada corporation entered into an Asset Purchase Agreement with Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation, pursuant to which Hatchtech sold all of its right, title and interest in (i) the product developed by Hatchtech with Abametapir as its sole… Filing
  14. Dec 23, 2025LeadershipThe Board of Directors of Pelthos Therapeutics Inc. expanded the number of members of the Board from seven to eight and appointed Andrew J. Einhorn to fill the vacancy created by such expansion. Filing
  15. Dec 17, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pelthos Therapeutics financials

Famous investors that hold PTHS

1 of the 50 well-known investors we track reported holding PTHS in their latest 13F filing. The largest position is Ken Griffin's, worth $325K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202615,453$325K0.0%+3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PTHS in the last 120 days.

FiledHolderFormStake
Nov 12, 20263i, LP13G/A9.9%
Nov 12, 20263i, LP13G/A9.9%
Nov 3, 2026Ligand Pharmaceuticals Incorporated13D/A49.9%
Nov 3, 2026Ligand Pharmaceuticals Incorporated13D/A49.9%

Questions about Pelthos Therapeutics Inc. (PTHS) stock

Who owns the most PTHS stock?

The largest reported owner of Pelthos Therapeutics Inc. (PTHS) is AIGH Capital Management LLC, with 9.8% of the company. In total, 23 funds and institutions reported holding PTHS at the end of Q2 2026, together about 41% of the shares. See the largest owners.

Are PTHS insiders buying or selling?

In the last 12 months, PTHS insiders reported 2 open-market purchases worth $1000K and 24 sales worth $486K. The latest trade was on Oct 2, 2026. See every trade.

What is the short interest in PTHS?

As of Oct 30, 2026, 158,465 PTHS shares were sold short, 4.1% of the shares outstanding, up 11.4% from the report before. At the average daily volume of 79,298 shares, buying them all back would take about 2.0 trading days (days to cover). See the history.

Which famous investors hold PTHS?

1 of the 50 well-known investors we track reported PTHS in their latest 13F filing, including Ken Griffin. The largest position is worth $325K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.